INS and type 1 diabetes mellitus: ONWARDS 6 (NCT04848480) was a 52-week (26-week main phase plus a 26-week safety extension phase), open-label, randomised, treat-to-target, phase 3a trial that enrolled a total of 582 T1DM patients, previously receiving basal-bolus therapy, randomized to receive either once-weekly icodec or once-daily insulin degludec, in combination with mealtime aspart (≥2 times per day).